-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As of now, some multinational pharmaceutical giants have successively released their 2021 performance reports, including Bristol-Myers Squibb, Roche, Merck, Sanofi, Eli Lilly,
etc.
Judging from various financial reports, many blockbuster oncology drugs have still brought dazzling performance to pharmaceutical giants, such as Bristol Squibb’s O drug, Merck’s K drug, Johnson & Johnson’s apalutamide, etc.
, but there are also product enhancements.
Slow down, such as Roche's Tecentriq
.
Opdivo On February 4, Bristol-Myers Squibb announced its 2021 results, with a total annual revenue of US$46.
385 billion, a year-on-year increase of 9%
.
In terms of product contribution, Revlimid (lenalidomide), Eliquis (apixaban), Opdivo (nivolumab), Orencia (abatacept), Pomalyst/Imnovid (pomalidomide), Sprycel (Dasatinib), Yervoy (ipilimumab) and Abraxane (albumin-paclitaxel) 8 products have combined sales revenue of more than $43 billion, accounting for 93% of the company's total revenue
.
Among them, the multiple myeloma drug lenalidomide (Revlimid) and the anticoagulant drug apixaban (Eliquis), the sales revenue reached 12.
821 billion US dollars and 10.
762 billion US dollars respectively
.
In addition, O drug is still a major driving force for the company's performance growth.
Although the sales of O drug declined in 2020, and encountered the withdrawal of second-line hepatocellular carcinoma and lung cancer indications after the second line in 2021, due to the product Active expansion of indications has also achieved certain results.
In 2021, O drugs for the first-line treatment of renal cell carcinoma, pleural mesothelioma, and gastric cancer will return to growth momentum, achieving sales revenue of US$7.
523 billion, a year-on-year increase of 8%
.
Keytruda On February 3, Merck announced its 2021 performance, with annual revenue of $48.
704 billion, a year-on-year increase of 17%
.
Among them, pembrolizumab (Keytruda, K drug) will continue to grow in 2021, mainly because the product continues to penetrate and penetrate into key cancer types such as NSCLC, triple-negative breast cancer, renal cell carcinoma, head and neck squamous cell carcinoma, and MSH-I.
Maintaining a large market advantage, and at the same time beginning to shift more to early first-line drugs in clinical drug use
.
Apalutamide Johnson & Johnson's 2021 financial report recently released shows that the total revenue for the year was US$93.
775 billion, a year-on-year increase of 13.
6%
.
Pharmaceutical business revenue was $52.
08 billion, up 14.
3% year-on-year
.
From the perspective of product contribution, Stelara (ustekinumab), Darzalex (daratumumab), Imbruvica (ibrutinib), Tremfya (gusekinumab), Erleada (apalutamide) ) and so on have achieved performance growth
.
Among them, apalutamide, which is used to treat prostate cancer, has had strong sales in recent years, with sales of US$1.
291 billion in 2021, a year-on-year increase of 70.
0%
.
Tecentriq's 2021 financial report shows that Roche achieved total revenue of CHF 62.
801 billion (about $69.
012 billion) throughout the year
.
Among them, Tecentriq in the oncology business segment is a humanized monoclonal antibody developed by Roche.
On October 18, 2016, the US FDA approved Tecentriq for the treatment of metastatic non-small cell tumors that progressed during or after platinum-containing chemotherapy.
Cell lung cancer (NSCLC) patients, or whose tumors have EGFR or ALK genetic abnormalities and have progressed on appropriate targeted therapy (FDA approved)
.
In 2021, Tecentriq achieved a 24% growth in performance, but it has slowed down significantly compared to the 55% growth in 2020, mainly due to the withdrawal of urothelial cancer, triple-negative breast cancer, and the failure of the first-line liver cancer COSMIC-312 study
.
But on the positive side, Tecentriq has also been approved as a PD-1/L1 product in the field of adjuvant lung cancer therapy in 2021, and is expected to gain incremental revenue in 2022
.
On the whole, although Roche will be driven by the revenue of oncology products such as Tecentriq in 2021, the company's "old troika" Avastin (bevacizumab) and Herceptin (trastuzumab), Rituxan (rituximab) xiximab) continued to suffer from the strong impact of biosimilars, and the overall oncology business segment revenue still fell by 11%
.
It is worth mentioning that in 2021, Roche’s Ocrevus, approved for the treatment of two types of multiple sclerosis, RRMS and PPMS, will reach CHF 5.
055 billion, making up for the decline in the revenue of Roche’s oncology drug segment.
This product is expected to be available in 2022.
continued growth
.
etc.
Judging from various financial reports, many blockbuster oncology drugs have still brought dazzling performance to pharmaceutical giants, such as Bristol Squibb’s O drug, Merck’s K drug, Johnson & Johnson’s apalutamide, etc.
, but there are also product enhancements.
Slow down, such as Roche's Tecentriq
.
Opdivo On February 4, Bristol-Myers Squibb announced its 2021 results, with a total annual revenue of US$46.
385 billion, a year-on-year increase of 9%
.
In terms of product contribution, Revlimid (lenalidomide), Eliquis (apixaban), Opdivo (nivolumab), Orencia (abatacept), Pomalyst/Imnovid (pomalidomide), Sprycel (Dasatinib), Yervoy (ipilimumab) and Abraxane (albumin-paclitaxel) 8 products have combined sales revenue of more than $43 billion, accounting for 93% of the company's total revenue
.
Among them, the multiple myeloma drug lenalidomide (Revlimid) and the anticoagulant drug apixaban (Eliquis), the sales revenue reached 12.
821 billion US dollars and 10.
762 billion US dollars respectively
.
In addition, O drug is still a major driving force for the company's performance growth.
Although the sales of O drug declined in 2020, and encountered the withdrawal of second-line hepatocellular carcinoma and lung cancer indications after the second line in 2021, due to the product Active expansion of indications has also achieved certain results.
In 2021, O drugs for the first-line treatment of renal cell carcinoma, pleural mesothelioma, and gastric cancer will return to growth momentum, achieving sales revenue of US$7.
523 billion, a year-on-year increase of 8%
.
Keytruda On February 3, Merck announced its 2021 performance, with annual revenue of $48.
704 billion, a year-on-year increase of 17%
.
Among them, pembrolizumab (Keytruda, K drug) will continue to grow in 2021, mainly because the product continues to penetrate and penetrate into key cancer types such as NSCLC, triple-negative breast cancer, renal cell carcinoma, head and neck squamous cell carcinoma, and MSH-I.
Maintaining a large market advantage, and at the same time beginning to shift more to early first-line drugs in clinical drug use
.
Apalutamide Johnson & Johnson's 2021 financial report recently released shows that the total revenue for the year was US$93.
775 billion, a year-on-year increase of 13.
6%
.
Pharmaceutical business revenue was $52.
08 billion, up 14.
3% year-on-year
.
From the perspective of product contribution, Stelara (ustekinumab), Darzalex (daratumumab), Imbruvica (ibrutinib), Tremfya (gusekinumab), Erleada (apalutamide) ) and so on have achieved performance growth
.
Among them, apalutamide, which is used to treat prostate cancer, has had strong sales in recent years, with sales of US$1.
291 billion in 2021, a year-on-year increase of 70.
0%
.
Tecentriq's 2021 financial report shows that Roche achieved total revenue of CHF 62.
801 billion (about $69.
012 billion) throughout the year
.
Among them, Tecentriq in the oncology business segment is a humanized monoclonal antibody developed by Roche.
On October 18, 2016, the US FDA approved Tecentriq for the treatment of metastatic non-small cell tumors that progressed during or after platinum-containing chemotherapy.
Cell lung cancer (NSCLC) patients, or whose tumors have EGFR or ALK genetic abnormalities and have progressed on appropriate targeted therapy (FDA approved)
.
In 2021, Tecentriq achieved a 24% growth in performance, but it has slowed down significantly compared to the 55% growth in 2020, mainly due to the withdrawal of urothelial cancer, triple-negative breast cancer, and the failure of the first-line liver cancer COSMIC-312 study
.
But on the positive side, Tecentriq has also been approved as a PD-1/L1 product in the field of adjuvant lung cancer therapy in 2021, and is expected to gain incremental revenue in 2022
.
On the whole, although Roche will be driven by the revenue of oncology products such as Tecentriq in 2021, the company's "old troika" Avastin (bevacizumab) and Herceptin (trastuzumab), Rituxan (rituximab) xiximab) continued to suffer from the strong impact of biosimilars, and the overall oncology business segment revenue still fell by 11%
.
It is worth mentioning that in 2021, Roche’s Ocrevus, approved for the treatment of two types of multiple sclerosis, RRMS and PPMS, will reach CHF 5.
055 billion, making up for the decline in the revenue of Roche’s oncology drug segment.
This product is expected to be available in 2022.
continued growth
.
